Trials / Not Yet Recruiting
Not Yet RecruitingNCT07185477
A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, single-arm, multicenter trial designed to evaluate the hematologic response rate and safety of GPRC5D/CD3 bispecific antibody bridging therapy prior to CAR-T cell infusion in patients with relapsed/refractory multiple myeloma (RRMM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | QLS32015 | QLS32015 is a GPRC5D × CD3 bispecific antibody. |
Timeline
- Start date
- 2025-09-15
- Primary completion
- 2027-05-31
- Completion
- 2028-05-31
- First posted
- 2025-09-22
- Last updated
- 2025-09-22
Source: ClinicalTrials.gov record NCT07185477. Inclusion in this directory is not an endorsement.